|3.||Chronic Hepatitis B
|5.||Chronic Hepatitis D
|1.||Wedemeyer, Heiner: 16 articles (12/2015 - 03/2009)|
|2.||Manns, Michael P: 12 articles (07/2014 - 01/2002)|
|3.||Zachou, Kalliopi: 9 articles (12/2015 - 01/2002)|
|4.||Casey, John L: 9 articles (07/2014 - 04/2002)|
|5.||Yurdaydin, Cihan: 7 articles (12/2015 - 08/2002)|
|6.||Heidrich, Benjamin: 7 articles (12/2015 - 06/2010)|
|7.||Bozkaya, Hakan: 7 articles (12/2015 - 08/2002)|
|8.||Abbas, Zaigham: 7 articles (08/2015 - 01/2011)|
|9.||Lai, Michael M C: 7 articles (01/2010 - 04/2002)|
|10.||Dalekos, George N: 6 articles (12/2015 - 11/2010)|
|1.||Hepatitis B Surface Antigens (HBsAg)FDA Link
10/01/1985 - "It is estimated that approximately 70 to 80% of the world's HBsAg carriers live in Southeast Asia, but studies of delta infection in this area are still limited. "
01/01/1983 - "This study demonstrates the presence of serological markers of delta infection in HBsAg positive patients throughout the years 1976-1982. "
01/01/2015 - "Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status."
11/01/2014 - "We followed 75 HBsAg-anti-HDV-positive patients with hepatitis delta for up to 16 years (median 5 years). "
11/01/2011 - "Delta hepatitis affects around 15% of HIV-infected individuals in Europe harbouring positive HBsAg. "
05/01/1996 - "Two children cleared hepatitis delta antigen (HDVAg) from the liver. "
11/01/1990 - "We conclude that immunization with this recombinant hepatitis delta antigen does not afford protection against subsequent hepatitis delta virus exposure."
05/01/2012 - "An anti-hepatitis delta (HD) enzyme-linked immunosorbent assay (ELISA) using a specific recombinant hepatitis delta antigen derived from a local dominant hepatitis delta virus (hepatitis D virus; HDV) strain in Taiwan has been established. "
12/01/2007 - "Slowing the rate of transcription or adding the hepatitis delta antigen protein only further stimulated cotranscriptional self-cleavage activity. "
05/01/2007 - "Likelihood ratio tests revealed a significant fitness of positive selection over neutrality of the hepatitis delta antigen gene in all patients. "
01/01/2012 - "The safety and efficacy of interferons in advanced delta hepatitis have not been explored. "
06/12/2012 - "A recent multi-center study highlighted that pegylated interferon α-2a (PEG-IFN) is currently the only treatment option for delta hepatitis. "
01/01/2015 - "Interferon lambda-3 polymorphism and response to pegylated interferon in patients with hepatitis D."
10/01/2011 - "Treatment options for hepatitis delta are limited, with only 25% of patients responding to interferon (IFN)-alfa-based therapies. "
06/01/2011 - "Reviving pegylated interferon as a therapeutic agent for hepatitis D: no more room for nucleos(t)ides?"
|4.||Hepatitis B e AntigensIBA
07/01/2003 - "Therefore, extra care in monitoring should be considered and strict follow-up is recommended, since clearance of hepatitis D may occur after HBeAg seroconversion in coinfected patients. "
10/01/2012 - "HBeAg-positive hepatitis delta was detected in 71 of 534 patients (13.3%). "
10/01/2012 - "HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome."
04/01/1989 - "Factors related to HBeAg/anti-HBe seroconversion were: female sex, higher mean starting values of transaminase, positive history for EVA, absence of Virus Delta superinfection. "
10/01/1986 - "The results were correlated to the HBeAg/anti-HBe status and to the presence of anti-delta as a marker for delta superinfection. "
|5.||DNA (Deoxyribonucleic Acid)IBA
01/01/1987 - "Eleven of 14 patients, who cleared hepatitis B virus DNA, did so following or at the same time as onset of delta-infection. "
09/01/1985 - "In addition patients with delta infection had a significantly increased hepatitis B virus DNA clearance rate as compared to patients without delta markers in their serum (p less than 0.01). "
09/01/1985 - "Hepatitis B virus DNA clearance was observed in a significantly higher proportion (87%) of delta-infected patients as compared to patients with no delta infection (45%) (p less than 0.05). "
08/01/1994 - "In the event of recurrence, severe graft injury is diminished in recent patients and in those with coexistent delta infection who also have lower levels of circulating HBV DNA. "
03/01/1989 - "Of the patients who were anti-HBe positive initially, 23 (54.8%) were diagnosed as having delta superinfection, including eight with de novo seroconversion of anti-delta and 15 with a rising titer of anti-delta; 10 (23.8%) were positive for hepatitis B virus DNA and were considered as reactivation of hepatitis B virus, and the other nine (21.4%) were suspected as having non-A, non-B virus superinfection.(ABSTRACT TRUNCATED AT 250 WORDS)"
|6.||Interferon-alpha (Interferon Alfa)FDA Link
11/01/2000 - "Currently, the best option for patients with hepatitis delta is interferon alpha therapy for at least one year. "
07/01/1998 - "In order to evaluate the efficacy and tolerability of interferon alpha in the treatment of hepatitis delta in HIV-infected patients, and to compare them with those observed in anti-HIV-seronegative patients, we carried out an open uncontrolled trial on 21 HIV-uninfected and 16 HIV-infected patients without severe immunodeficiency. "
04/01/2014 - "Our data suggest that interleukin-28B polymorphisms might not influence hepatitis delta clearance rate in either natural history or interferon-alpha response."
01/01/2011 - "Interferon alpha does not seem to cure hepatitis D in most patients. "
11/01/1989 - "Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses."
|7.||Immunoglobulin M (IgM)IBA
01/01/1989 - "The study of the chromatographic profiles of IgM anti-delta in the development of the disease showed an association between the process of chronic delta-infection and the failure of 7S IgM anti-delta monomers to form 19S pentamers. "
01/01/2014 - "Serum anti-HDV IgM is a robust, easy-to-apply and relatively cheap marker to determine disease activity in hepatitis delta which has prognostic implications. "
01/01/2014 - "Anti-HDV IgM as a marker of disease activity in hepatitis delta."
01/01/2012 - "Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment."
08/01/1987 - "Overall, serum HD-Ag and anti-HD IgM were the most sensitive markers for diagnosis of delta infection during the first 2 weeks after onset of symptoms. "
12/01/2011 - "Hepatitis delta in HIV/HBV co-infected patients in Brazil: is it important?"
04/01/1992 - "Co-expression of markers for hepatitis delta and hepatitis B viruses in human liver."
09/24/1987 - "Human hepatitis delta (delta) virus (HDV) is a form of defective virus, which infects humans only in the presence of a co-infecting hepatitis B virus (HBV). "
03/01/2013 - "Further studies are needed to draw a firm conclusion with regard to the hepatocarcinogenic effect of dual Delta/hepatitis B virus co-infection. "
05/01/2007 - "This study was carried out to determine the seroprevalence of HBV and its co-infection with hepatitis D (HDV) and C (HCV) viruses in the northeastern part of Iran. "
09/01/1998 - "Their antigenic activities were assessed by indirect enzyme immunoassay with sera of patients with hepatitis D and of asymptomatic carriers of anti-delta antibodies. "
11/01/1991 - "From 1973 to 1989 five patients with hepatitis delta virus having anti-hepatitis delta antibodies continuously in the serum for more than 5 years were identified among 1019 hepatitis B virus carriers who were being followed-up for more than 3 years (mean 8.9 years). "
10/01/1989 - "The prevalence of delta infection varied between geographically isolated subgroups in the population and delta antibodies were found more frequently in subjects over the age of 10. "
01/01/1987 - "Unexpected low prevalence of delta antibodies in the east Amazon region and São Paulo: evidence for regional differences in the epidemiology of delta hepatitis virus within Brazil."
01/01/1987 - "Furthermore, the finding that these two antibodies were also associated with hepatitis D would support the possibility that NANB agents and the HDV may have a similar nature or may elicit a similar host response."
|10.||Hepatitis B Vaccines (Hepatitis B Vaccine)IBA
09/01/1987 - "There is as yet no known effective treatment for established delta infection, and, for the present, clinicians must concentrate on preventing HDV infection by incorporating vigorous use of the hepatitis B vaccine into strategies for preventing HBV infection."
06/01/1989 - "To assess the incidence and prevalence of delta hepatitis in homosexual men, we tested serum specimens for delta markers in participants in two previous studies: a hepatitis B vaccine trial among homosexual men conducted in the early 1980's and the Centers for Disease Control sentinel counties hepatitis study for 1983-1984. "
05/01/2003 - "Worldwide use of hepatitis B vaccines for the newborn, young children and high-risk groups should control this infection and obviate the need for a vaccine against hepatitis D. "
03/01/1990 - "The present study was undertaken to determine the effectiveness of our immunoprophylaxis regimen (hepatitis B immune globulin at 36-72 h, hepatitis B vaccine at 36-72 h, 1 month and 6 months) in eliciting protective antibody to hepatitis B surface antigen (anti-HBs) in the infants of these women, the rate of perinatal transmission of HBV in this population prior to vaccination, the prevalence of anti-hepatitis delta antibody (anti-HD), and the prevalence of liver disease in our hepatitis B surface antigen-positive (HBsAg+) population. "
|1.||Transplantation (Transplant Recipients)
10/01/1992 - "The clinical course of 10 liver transplant recipients who had hepatitis B virus (HBV) and five recipients with HBV and D (delta) infection before transplantation is described. "
03/01/1998 - "In 5 patients who underwent transplantation and who became reinfected with HDV, the antibody remained undetectable during the early reinfection phase, as marked by HDV replication and by the absence of liver damage; however, it rapidly raised to pre-transplantation levels with the recurrence of hepatitis D (HD) in the liver graft. "
03/01/1992 - "The study shows: in the case of fulminant hepatitis, 93% success versus 77% in post hepatitis cirrhosis; in the case of Delta superinfection, 94% success versus 66% with pure B infection; in the absence of HBVDNA in the patient's sera before transplantation, 92% success versus 20% in the presence of HBVDNA. "
01/02/1988 - "Delayed clearance of HBsAG after transplantation for fulminant delta-hepatitis."
08/01/2005 - "Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection."
09/01/2011 - "In this study, we sought to evaluate the efficacy of treatment with pegylated interferon and observe the relapse rates of delta hepatitis after treatment. "
11/01/1991 - "Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-alpha."
|3.||Blood Transfusion (Blood Transfusions)
02/01/1986 - "A higher prevalence of delta infection and increased incidence of blood transfusions were observed in patients with cirrhosis, supporting the hypothesis that superinfection with delta or non-A, non-B agents may play a synergistic role. "
12/01/2014 - "Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization."